1. Home
  2. MOS vs ERAS Comparison

MOS vs ERAS Comparison

Compare MOS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mosaic Company (The)

MOS

Mosaic Company (The)

N/A

Current Price

$22.49

Market Cap

6.0B

Sector

Industrials

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

N/A

Current Price

$14.36

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MOS
ERAS
Founded
1987
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.3B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
MOS
ERAS
Price
$22.49
$14.36
Analyst Decision
Buy
Buy
Analyst Count
20
9
Target Price
★ $25.66
$24.11
AVG Volume (30 Days)
★ 10.7M
4.8M
Earning Date
11-03-2026
11-20-2026
Dividend Yield
★ 3.94%
N/A
EPS Growth
★ 209.09
36.23
EPS
N/A
★ N/A
Revenue
★ $12,052,400,000.00
N/A
Revenue This Year
$0.65
N/A
Revenue Next Year
$6.03
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 8.36
N/A
52 Week Low
$16.99
$2.21
52 Week High
$32.25
$24.28

Technical Indicators

Market Signals
Indicator
MOS
ERAS
Relative Strength Index (RSI) 66.21 45.10
Support Level $20.48 $13.47
Resistance Level $24.00 $15.71
Average True Range (ATR) 0.89 1.07
MACD 0.70 -0.03
Stochastic Oscillator 96.47 37.55

Price Performance

Historical Comparison
MOS
ERAS

About MOS Mosaic Company (The)

Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in the US and potash mines in Canada. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: